Kiniksa Pharmaceuticals Corporate Presentation May 2023

Kiniksa Pharmaceuticals is a biopharmaceutical company with a portfolio of immune-modulating assets across cardiovascular and autoimmune indications. The company's lead asset ARCALYST (rilonacept) is approved for recurrent pericarditis and other conditions, supported by additional clinical-stage candidates including mavrilimumab and KPL-404. Kiniksa has established out-licensing agreements with Huadong Medicine and Roche/Genentech for geographic expansion of its product candidates.